RM-11, an isoxazole derivative, accelerates restoration of the immune function in mice treated with cyclophosphamide

Michał Zimecki¹, Jolanta Artym¹, Stanisław Ryng², Bożena Obmińska-Mrukowicz³

¹Laboratory of Immunology, Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Węglicka 12, PL 50-114 Wrocław, Poland
²Department of Organic Chemistry, Faculty of Pharmacy, Wrocław Medical University, Grodzka 9, PL 51-351 Wrocław, Poland
³Department of Biochemistry, Pharmacology and Toxicology, Faculty of Veterinary Medicine, Wrocław University of Environmental and Life Sciences, Norwida 25/27, PL 50-375 Wrocław, Poland

Correspondence: Michał Zimecki, e-mail: zimecki@iiti.pan.wroc.pl

Abstract:
The aim of this study was to evaluate efficacy of an isoxazole derivative RM11 to accelerate reconstitution of selected immune activities in cyclophosphamide (CP)-immunocompromised mice. We demonstrated that administration of fifteen 10 µg intraperitoneal doses of RM11, following a sublethal (200 µg/kg) dose of CP, significantly stimulated the number of antibody-forming cells (AFC) to sheep erythrocytes (SRBC) as determined 35 days after the CP treatment. Similarly, treatment of the CP-injected mice with 7 doses of RM11 significantly enhanced generation of delayed type hypersensitivity (DTH) to ovalbumin (OVA). Moreover, in that model, the treatment of mice with RM11 accelerated the process of myelopoiesis. RM11 also counteracted the suppressive action of methotrexate (MTX) in the in vitro model of the humoral immune response to SRBC. The phenotypic studies with fluorocytometer revealed that intraperitoneal 10 µg dose of RM11 significantly elevated the percentage of mature (CD3⁺, CD4⁺ and CD8⁺) T cells in the spleen and down-regulated the content of CD19⁺ cells. We conclude that RM11 may be of potential therapeutic value in restoration of the immune status in patients undergoing chemotherapy.

Key words:
isoazoles, mice, immune response, cyclophosphamide, methotrexate